Persistent Asset Partners Ltd Lowers Holdings in Replimune Group, Inc. $REPL

Persistent Asset Partners Ltd lessened its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 56.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,492 shares of the company’s stock after selling 9,651 shares during the period. Persistent Asset Partners Ltd’s holdings in Replimune Group were worth $70,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Bank of New York Mellon Corp lifted its position in Replimune Group by 8.4% in the first quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company’s stock valued at $1,844,000 after buying an additional 14,659 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock valued at $151,000 after acquiring an additional 2,545 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Replimune Group by 67.4% in the 1st quarter. Victory Capital Management Inc. now owns 75,140 shares of the company’s stock worth $733,000 after acquiring an additional 30,260 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Replimune Group by 106.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock worth $111,000 after acquiring an additional 5,876 shares during the last quarter. Finally, US Bancorp DE boosted its position in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after purchasing an additional 3,921 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Trading Up 0.1%

REPL opened at $8.99 on Friday. The business has a fifty day moving average price of $6.45 and a 200 day moving average price of $7.42. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.94. Replimune Group, Inc. has a 12 month low of $2.68 and a 12 month high of $17.00. The stock has a market capitalization of $705.18 million, a price-to-earnings ratio of -2.60 and a beta of 0.80.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Sell-side analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on REPL. Jefferies Financial Group cut their target price on Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. HC Wainwright upgraded Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, October 27th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their target price for the company from $3.00 to $13.00 in a report on Monday, October 20th. BMO Capital Markets downgraded Replimune Group from an “outperform” rating to an “underperform” rating and dropped their target price for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Finally, Piper Sandler raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a research report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.75.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.